ROLE OF AMBROXOL AS A PROPHYLACTIC AGENT AGAINST COVID-19

  • Azza M. Baraka Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Egypt.
  • Wessam F. El-Hadidy Department of Pharmacology and Experimental Therapeutics, Medical Research Institute, Alexandria University, Egypt.
10.22270/ujpr.v6i1.542

Keywords:

Ambroxol, Coronavirus disease 2019 “COVID-19”, mucokinetic drug, Type II transmembrane serine protease “TMPRSS2

Abstract

Currently the world is facing a pandemic disease, namely Coronavirus disease 2019 (COVID-19) that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As finding recent drugs targeting COVID-19 will take a long time, so repositioning currently existing FDA approved drugs for treating this disastrous disease is an acceptable solution. It has been found that for SARS-CoV-2 to be infective, this necessitates splitting of the viral spike glycoproteins by the serine protease “type II transmembrane serine protease TMPRSS2” that has shown to be widely expressed in pulmonary tissues. Thus, TMPRSS2 is suggested to be potential target for antiviral drug design against COVID-19.  The mucokinetic drug “Ambroxol” has been reported as a potent inhibitor of TMPRSS2, thus it could represent a therapeutic as well as a prophylactic candidate against SARS-CoV2. This review gives a brief summary about ambroxol’s potential role against COVID-19’s TMPRSS2.

                           rw3.gif

Peer Review History:

Received 2 December 2020; Revised 6 January 2021; Accepted 10 February; Available online 15 March 2021

Academic Editor: Dr. DANIYAN Oluwatoyin Michaelorcid22.jpg, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.com

Received file:blue_23983.gif                Reviewer's Comments:download_logo_r_29189.gif

Average Peer review marks at initial stage: 5.5/10

Average Peer review marks at publication stage: 7.0/10

Reviewer(s) detail:

Dr. Nuray Arıorcid22.jpg, Ankara University, Turkiye, ari@ankara.edu.tr

Prof. Cyprian Ogbonna ONYEJIorcid22.jpg, Obafemi Awolowo University, Ile-Ife, Nigeria, conyeji@oauife.edu.ng

Dr. Asia Selman Abdullahorcid22.jpg, Al-Razi university, Department of Pharmacy, Yemen, asia_abdullah65@yahoo.com

Downloads

Download data is not yet available.
Crossmark
Statistics
310 Views | 175 Downloads
Dimension Citations

Published

2021-03-15

How to Cite

Baraka, A. M., and W. F. El-Hadidy. “ROLE OF AMBROXOL AS A PROPHYLACTIC AGENT AGAINST COVID-19”. Universal Journal of Pharmaceutical Research, vol. 6, no. 1, Mar. 2021, doi:10.22270/ujpr.v6i1.542.

Issue

Section

Review Articles
Share |